Wilbur A Franklin
Overview
Explore the profile of Wilbur A Franklin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
6977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jonsson S, Franklin W, Varella-Garcia M, Kennedy T, Merrick D, Matney K, et al.
APMIS
. 2023 Aug;
131(10):513-527.
PMID: 37608782
Bronchial squamous carcinoma in situ (CIS) is a preinvasive lesion that is thought to precede invasive carcinoma. We conducted prospective autofluorescence and white light bronchoscopy trials between 1992 and 2016...
2.
Keith R, Miller Y, Ghosh M, Franklin W, Nakachi I, Merrick D
Semin Oncol
. 2022 Mar;
49(3-4):254-260.
PMID: 35305831
Lung cancer (both adenocarcinoma and squamous cell) progress through a series of pre-malignant histologic changes before the development of invasive disease. Each of these carcinogenic cascades is defined by genetic...
3.
Bueno R, Richards W, Harpole D, Ballman K, Tsao M, Chen Z, et al.
J Thorac Oncol
. 2020 Jul;
15(11):1748-1757.
PMID: 32717408
Introduction: Surgical resection is curative for some patients with early lung squamous cell carcinoma. Staging and clinical factors do not adequately predict recurrence risk. We sought to validate the discriminative...
4.
Nakajima E, Sugita M, Furukawa K, Takahashi H, Uchida O, Kawaguchi Y, et al.
Oncol Lett
. 2019 Jun;
17(6):5125-5131.
PMID: 31186726
Epidermal growth factor receptor (EGFR) is the most important driver gene of non-small cell lung cancer (NSCLC) as EGFR mutations determine the efficacy of EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy....
5.
Yu H, Chen Z, Ballman K, Watson M, Govindan R, Lanc I, et al.
J Thorac Oncol
. 2018 Sep;
14(1):25-36.
PMID: 30253973
Objectives: Anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small...
6.
Merrick D, Edwards M, Franklin W, Sugita M, Keith R, Miller Y, et al.
Cancer Res
. 2018 Jul;
78(17):4971-4983.
PMID: 29997230
Persistent bronchial dysplasia is associated with increased risk of developing invasive squamous cell carcinoma (SCC) of the lung. In this study, we hypothesized that differences in gene expression profiles between...
7.
Ghosh M, Miller Y, Nakachi I, Kwon J, Baron A, Brantley A, et al.
Am J Respir Crit Care Med
. 2017 Dec;
197(7):885-896.
PMID: 29211494
Rationale: Up to 40% of smokers develop chronic obstructive pulmonary disease (COPD) over a period that spans decades. Despite the importance of COPD, much remains to be learned about susceptibility...
8.
Wang M, Lomeli S, Franklin W, Lee S, Pantuck A, Zeng G
Am J Clin Exp Immunol
. 2017 Nov;
6(5):84-91.
PMID: 29181273
Autoantibody (autoAb) response is an important arm of endogenously arising anti-tumor immune responses, and has received new attention as a cancer biomarker with the recent success of immune check-point inhibitor...
9.
Nicholson A, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk A, et al.
J Thorac Oncol
. 2017 Nov;
13(2):205-217.
PMID: 29127023
Multiple tumor nodules are seen with increasing frequency in clinical practice. On the basis of the 2015 WHO classification of lung tumors, we assessed the reproducibility of the comprehensive histologic...
10.
Bruno T, Ebner P, Moore B, Squalls O, Waugh K, Eruslanov E, et al.
Cancer Immunol Res
. 2017 Aug;
5(10):898-907.
PMID: 28848053
Effective immunotherapy options for patients with non-small cell lung cancer (NSCLC) are becoming increasingly available. The immunotherapy focus has been on tumor-infiltrating T cells (TILs); however, tumor-infiltrating B cells (TIL-Bs)...